Pharma manufacturing spent 90 years learning that producing correct outputs isn't the same as catching your own errors. AI has only learned the first.
News|Articles|September 14, 2022
WHO Grants Prequalification to GSK’s Malaria Vaccine
Author(s)Pharmaceutical Technology Editors
WHO has awarded prequalification to GSK’s Mosquirix, an approved malaria vaccine.
Advertisement
GSK announced on Sept. 6, 2022 that the World Health Organization (WHO) has awarded prequalification to Mosquirix, GSK’s malaria vaccine. This is the first prequalification for a malaria vaccine, according to a company press release. The WHO’s decision is an important step to beginning the process of distributing the vaccine in countries with moderate to high malaria transmission.
The WHO prequalification is a mandatory prerequisite for United Nations agencies, such as UNICEF, to gain vaccine partnership with Gavi, the Vaccine Alliance, and eligible countries. GSK was determined to meet standards of quality, safety, and efficacy with its vaccine before prequalification.
“WHO prequalification of Mosquirix is a key step in reaching children with [this] malaria vaccine,” said Thomas Breuer, chief global health officer, GSK, in a company press release. “Malaria remains a significant cause of illness and death for children in many parts of the world, and it is a significant driver of inequality. So far, [more than one] million children in Ghana, Kenya, and Malawi have had at least one dose of Mosquirix, donated by GSK, through the Malaria Vaccine Implementation [Program], and WHO’s prequalification paves the way for more children to benefit from the vaccine.”
Source:
Advertisement
Related to this article
This week on PharmTech, Merck diversified its pipeline, USP emphasizes supply chain security, AI systems are examined, and speakers preview their presentations at CPHI Milan and AAPS PharmSci 360.
Capsugel's Bram Baert and Sandrine Picco argue that chasing zero nitrite in pharmaceutical excipients is often impractical and costly. They recommend setting scientifically justified, risk-based limits and consistently staying below them.
The FDA opened an expedited IND pilot, tightened scrutiny of foreign trial data, and finalized a rule recognizing non-animal testing methods. In Europe, the EMA advanced pharmaceutical legislation reform, restricted 2 legacy products, and opened an injectable-iron safety review.
Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.
Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.
Michael Levy, senior vice president, Digital & Innovation, USP, explains the digital supply chain in a preview of his upcoming CPHI Milan panel presentation, The Next Phase of Pharma Supply Chains.
FDA approves tavapadon, first D1/D5 agonist, validating AbbVie's $8.7B Cerevel deal and an October five-strength oral tablet launch.
Advertisement
Advertisement